Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
- Conditions
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-fluorouracilDrug: FulvestrantDrug: LeucovorinDrug: PaclitaxelDrug: omega-3 acid ethyl estersDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6301Biological: haNK®
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197584
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 1150
- Registration Number
- NCT03182634
- Locations
- 🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧Royal Marsden Hosital, Sutton, England, United Kingdom
🇬🇧Clatterbridge Cancer Centre, Liverpool, United Kingdom
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03179904
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Conditions
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineBiological: cetuximabDrug: CyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: oxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineBiological: CetuximabDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelBiological: nivolumabDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Conditions
- Interventions
- Biological: avelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
Palbociclib After CDK and Endocrine Therapy (PACE)
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 220
- Registration Number
- NCT03147287
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT03134638
- Locations
- 🇺🇸
Palo Alto Medical Foundation Group, San Francisco, California, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT03099174
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.